Eris Lifesciences: Costly prescription

Segments it operates in offer scope for growth but valuations too expensive for comfort

A focus on faster-growing chronic therapy segments, especially cardiovascular and anti-diabetes, has helped Ahmedabad-based pharma company Eris Lifesciences to post faster growth rates than peers. While the top 35 companies in the Indian pharma market have grown their domestic revenues by an average of 12 per cent over the FY13-17 period, Eris has grown its revenues by 21.7 per cent. 

Though the chronic segment accounts for a third of the industry revenues (the other being the acute segment), it accounts for two-thirds of the company’s revenues. Even within the chronic space, while the sector’s growth in cardiovascular and anti-diabetes has